COMPANY INSIGHT

Sponsored by Hapa

How Hapa is helping MSD to implement late stage customization of blisters

Pharma Tech Focus speaks to MSD about how Hapa’s BlisterJet has helped to cope with their strategy of delivering within 24 hours of receiving an order.

The World Health Organisation estimates 1 in 50 people worldwide suffer from chronic Hepatitis C. In 2016, MSD a subsidiary of Merck & co. launched Zepatier to combat this disease. MSD confirmed that the list price for Zepatier would be $54,600 for a 12 week course, and with the high-cost associated with Zepatier, MSD confirmed it would be not be produced on a mass-scale. Stijn Van Kelst Sr. Specialist, Packaging Technology & Manufacturing Automation at MSD explains why they chose Hapa’s BlisterJet to get Zepatier to market.

"In 2015 MSD Belgium was selected for the packaging of Zepatier for all markets worldwide, the big difference with other products was we needed to supply the market within 24 hours of receiving an order and the quantity could be anywhere from 10 up to 10,000. We normally pack on lines that produce thousands per hour but now we needed to be able to pack just 10 products for a specific market. That is why we chose Hapa, so we can print on every individual blister with market specific information and manage small volumes."

No margin for error

"The Zepatier is very very expensive so we could not waste any product, neither on site nor in the market. So if we receive an order for 20 packs we must supply 20 packs not 21 or 25. We hold no finished goods inventory of the product so we must supply the exact amount for an order and that was the solution we found with late stage customisation using Hapa’s BlisterJet."

Success breeds new opportunities 

Hapa’s technology allows easy changeover of formats which allows for different artworks depending on the country being supplied into. Such has been the impact of Hapa’s technology, MSD has adopted an identical process with other products.

"After the Zepatier concept we did an extension and relocation of the line which included more space for the BlisterJet so we could pack more blisters per hour. The Zepatier concept was so successful that our site in Heist was chosen for a selection of new similarly low-volume, high value products and the reason why the business came to our site was because we already had the late stage customization concept in place; At the moment we pack 5 different products on that line for markets worldwide."

Customer orientated solutions

Hapa prides itself on building long term key relationships with most of the biggest pharmaceutical companies in the world with a focus on customer service.

"Hapa’s customer service has been incredibly efficient with a very quick response time. For a big project we had some difficulty printing in 2 colors, however Hapa looked for a solution for us to be able to print these colors on a blister with a very quick turnaround, we will continue to work with Hapa for many years to come."

About MSD

We are committed to improving health and well-being around the world. This includes developing new therapies that treat and prevent diseases and helping people in need.

About Hapa

Our mission is to empower our customers to improve lean production with printing solutions that add value to packaging processes. We are a proud supplier to nearly all of the major pharmaceutical companies worldwide.

THE BIGGEST ADVANTAGES OF THE BLISTERJET IS WE HAVE NO PRODUCT WASTE IN THE MARKET, WE HAVE A FAST DELIVERY, HIGH FLEXIBILITY AND HIGH RESPONSIVENESS.

Go to article: Home | The dengue dilemma Go to article: In this issueGo to article: Owen MumfordGo to article: ContentsGo to article: Hapa Company Insight Go to article: Daiichi JitsugyoGo to article: NewsGo to article: EmbocapsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: The pharma industry briefingGo to article: Dow Europe Company InsightGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The problem of manipulated data Go to article: Capsugel Company Insight Go to article: CapsugelGo to article: Timeline: the dengue vaccine dilemmaGo to article: TSS Company Insight Go to article: TSSGo to article: From evergreening to thicketing: exploring manipulation of the pharma patent sysGo to article: Emirates SkyCargoGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Swiss WorldCargoGo to article: Accurate BiometricsGo to article: Accurate Biometrics Company Insight Go to article: Nelson LabsGo to article: Treading the line: the challenge of transplant rejection drugsGo to article: Corbion PuracGo to article: Erdmann Design Company InsightGo to article: Erdmann Design SwitzerlandGo to article: Treating menopause: at last a non-hormonal alternative? Go to article: YourwayGo to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Drug repurposing: the industry’s all-rounder medicinesGo to article: FargoGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: One step closer to a Chlamydia vaccine Go to article: AralabGo to article: Synex SyntheticsGo to article: Deals in brief powered by GlobalDataGo to article: Charles Ischi Go to article: The key list powered by GlobalDataGo to article: Pharmaceutical Solutions IndustryGo to article: Clinichain Company Insight Go to article: ClinichainGo to article: SanofiGo to article: EventsGo to article: NymiGo to article: Modality SolutionsGo to article: PfanstiehlGo to article: Next issueGo to article: MimotopesGo to article: ICCI - International Cannabis and Cannabinoids Institute Go to article: ICCI